Loading...
Market
What will be identified as the primary benefit of using AI in prostate cancer diagnostics by the ARTICULATE PRO study by the end of 2024?
2
Resolution / Starting Odds
Improved diagnostic accuracy • 25%
Faster diagnosis times • 25%
Better resource utilization • 25%
Other • 25%
Study results published by the ARTICULATE PRO researchers or official press releases from the involved hospital systems.
Story
AI Boosts Cancer Detection Rates by 8% in England
Jul 22, 2024, 11:03 AM
Artificial intelligence (AI) is making significant strides in the field of cancer diagnosis and treatment. In England, general practitioners (GPs) have utilized an AI-powered tool called 'C the Signs' to increase cancer detection rates by a remarkable 8%. This tool scans medical records to identify patterns that may be missed by human doctors, enabling faster and earlier diagnoses. Additionally, three UK-based hospital systems are conducting live clinical trials of Paige's AI technology, which aims to enhance prostate cancer diagnostics. This study, known as ARTICULATE PRO, is evaluating how AI can improve clinical decision-making, pathology service delivery, and resource utilization in live clinical settings.
View original story
Similar markets
Improved diagnostic accuracy • 25%
Reduced diagnostic time • 25%
Cost savings • 25%
Improved patient satisfaction • 25%
Early-stage detection • 25%
Mid-stage detection • 25%
Late-stage detection • 25%
Not specified • 25%
Improved diagnostic accuracy • 25%
Reduced administrative workload • 25%
Addressed staffing shortages • 25%
Enhanced patient management • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Colorectal Cancer • 25%
Less than 5% • 25%
5% - 10% • 25%
11% - 15% • 25%
More than 15% • 25%
Neonatal care • 25%
Pediatric care • 25%
General radiology • 25%
Other • 25%
0-5% improvement • 25%
6-10% improvement • 25%
11-15% improvement • 25%
More than 15% improvement • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Prostate Cancer • 25%
Colon Cancer • 25%
Rectal cancer • 25%
Breast cancer • 25%
Lung cancer • 25%
Other • 25%
MIT • 33%
ETH Zurich • 33%
Other collaborating institution • 33%
None • 1%